blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2046815

EP2046815 - ANTI-INFLAMMATORY AND ANTIALLERGIC CYCLIC PEPTIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.06.2013
Database last updated on 26.04.2025
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU
published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA.
Rodovia Itapira/Iindoia, Km 14
13970-000 Itapira / BR
For all designated states
Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP
Rua Pio XI, 1500 - Alto da Lapa
05468-901 São Paulo / BR
For all designated states
Ferreira, Mônica
Av. Vital Brasil 1500 Laboratório Especial De Toxicologia Aplicada Instituto Butantan Centro DeToxicologiaAplicada/cepid
05503-900 São Paulo / BR
[2009/16]
Inventor(s)01 / FERREIRA, Mônica
Av. Vital Brasil 1500
Laboratório Especial De Toxicologia Aplicada
Instituto Butantan
Centro DeToxicologiaAplicada/cepid
05503-900 São Paulo / BR
02 / SILVA, Carla
Av. Vital Brasil, 1500
Laboratório Especial De Toxicologia Aplicada
Instituto Butantan
Centro DeToxicologia Aplicada/cepid
05503-900 São Paulo / BR
03 / PIMENTA, Daniel
Av. Vital Brasil, 1500
Laboratório De Bioquímica
E Biofísica
Instituto Butantan
05503-900 São Paulo / BR
04 / PORTARO, Fernanda
Av. Vital Brasil, 1500
Laboratório De Imunoquímica
Instituto Butantan
05503-900 São Paulo / BR
05 / CONCEIÇÃO, Kátia
Av. Vital Brasil, 1500
Laboratório Especial
De Toxicologia Aplicada
Instituto Butantan, Centro DeToxicologia Aplicada/cepid
05503-900 São Paulo / BR
06 / DEMASI, Marilene
Av. Vital Brasil, 1500
Laboratório De Bioquímica
E Biofísica
Instituto Butantan
05503-900 São Paulo / BR
 [2012/32]
Former [2009/16]01 / FERREIRA, Mônica
Av. Vital Brasil 1500 Laboratório Especial De Toxicologia Aplicada Instituto Butantan Centro DeToxicologiaAplicada/cepid
05503-900 São Paulo / BR
02 / SILVA, Carla
Av. Vital Brasil, 1500 Laboratório Especial De Toxicologia Aplicada Instituto Butantan Centro DeToxicologia Aplicada/cepid
05503-900 São Paulo / BR
03 / PIMENTA, Daniel
Av. Vital Brasil, 1500 Laboratório De Bioquímica E Biofísica Instituto Butantan
05503-900 São Paulo / BR
04 / PORTARO, Fernanda
Av. Vital Brasil, 1500 Laboratório De Imunoquímica Instituto Butantan
05503-900 São Paulo / BR
05 / CONCEIÇÃO, Kátia
Av. Vital Brasil, 1500 Laboratório Especial De Toxicologia Aplicada Instituto Butantan Centro DeToxicologia Aplicada/cepid
05503-900 São Paulo / BR
06 / DEMASI, Marilene
Av. Vital Brasil, 1500 Laboratório De Bioquímica E Biofísica Instituto Butantan
05503-900 São Paulo / BR
Representative(s)Alves Moreira, Pedro
Raul César Ferreira (Herd.), Lda.
Rua do Patrocinio, 94
1399-019 Lisbon / PT
[N/P]
Former [2012/32]Alves Moreira, Pedro
Raul César Ferreira (Herd.), Lda. Rua do Patrocinio, 94
1399-019 Lisbon / PT
Former [2009/16]Alves Moreira, Pedro
Raul César Ferreira (Herd.), Lda. Rua do Patrocinio, 94
1399-019 Lisbon / PT
Application number, filing date07784915.619.07.2007
[2009/16]
WO2007BR00186
Priority number, dateBR2006PI0288521.07.2006         Original published format: BR PI0602885
BR2007PI0317504.07.2007         Original published format: BR PI0703175
[2010/11]
Former [2009/16]BR2006PI0288521.07.2006
BR2007PI9049904.07.2007
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008009085
Date:24.01.2008
Language:EN
[2008/04]
Type: A1 Application with search report 
No.:EP2046815
Date:15.04.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 24.01.2008 takes the place of the publication of the European patent application.
[2009/16]
Type: B1 Patent specification 
No.:EP2046815
Date:08.08.2012
Language:EN
[2012/32]
Search report(s)International search report - published on:AT24.01.2008
(Supplementary) European search report - dispatched on:EP25.08.2010
ClassificationIPC:C07K7/64, C07K7/08, C07K14/46, C07K14/81
[2010/38]
CPC:
C07K14/461 (EP); C07K14/811 (EP); C07K7/08 (EP);
A61K38/00 (EP)
Former IPC [2009/16]C07K7/64
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/16]
TitleGerman:ENTZÜNDUNGSHEMMENDE UND ANTIALLERGISCHE CYCLISCHE PEPTIDE[2009/16]
English:ANTI-INFLAMMATORY AND ANTIALLERGIC CYCLIC PEPTIDES[2009/16]
French:PEPTIDES CYCLIQUES ANTI-INFLAMMATOIRES ET ANTIALLERGIQUES[2009/16]
Entry into regional phase28.01.2009National basic fee paid 
28.01.2009Search fee paid 
28.01.2009Designation fee(s) paid 
28.01.2009Examination fee paid 
Examination procedure28.01.2009Examination requested  [2009/16]
11.03.2011Amendment by applicant (claims and/or description)
15.09.2011Despatch of a communication from the examining division (Time limit: M04)
13.01.2012Reply to a communication from the examining division
19.03.2012Communication of intention to grant the patent
28.06.2012Fee for grant paid
28.06.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.09.2011
Opposition(s)10.05.2013No opposition filed within time limit [2013/29]
Fees paidRenewal fee
28.01.2009Renewal fee patent year 03
23.06.2010Renewal fee patent year 04
20.05.2011Renewal fee patent year 05
19.04.2012Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.07.2007
AT08.08.2012
BE08.08.2012
CY08.08.2012
CZ08.08.2012
DK08.08.2012
EE08.08.2012
FI08.08.2012
IT08.08.2012
LT08.08.2012
LV08.08.2012
MC08.08.2012
MT08.08.2012
PL08.08.2012
RO08.08.2012
SE08.08.2012
SI08.08.2012
SK08.08.2012
TR08.08.2012
BG08.11.2012
GR09.11.2012
ES19.11.2012
IS08.12.2012
PT10.12.2012
[2015/34]
Former [2015/32]AT08.08.2012
BE08.08.2012
CY08.08.2012
CZ08.08.2012
DK08.08.2012
EE08.08.2012
FI08.08.2012
IT08.08.2012
LT08.08.2012
LV08.08.2012
MC08.08.2012
MT08.08.2012
PL08.08.2012
RO08.08.2012
SE08.08.2012
SI08.08.2012
SK08.08.2012
TR08.08.2012
BG08.11.2012
GR09.11.2012
ES19.11.2012
IS08.12.2012
PT10.12.2012
Former [2014/14]AT08.08.2012
BE08.08.2012
CY08.08.2012
CZ08.08.2012
DK08.08.2012
EE08.08.2012
FI08.08.2012
IT08.08.2012
LT08.08.2012
LV08.08.2012
MC08.08.2012
PL08.08.2012
RO08.08.2012
SE08.08.2012
SI08.08.2012
SK08.08.2012
BG08.11.2012
GR09.11.2012
ES19.11.2012
IS08.12.2012
PT10.12.2012
Former [2013/34]AT08.08.2012
BE08.08.2012
CY08.08.2012
CZ08.08.2012
DK08.08.2012
EE08.08.2012
FI08.08.2012
IT08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
RO08.08.2012
SE08.08.2012
SI08.08.2012
SK08.08.2012
BG08.11.2012
GR09.11.2012
ES19.11.2012
IS08.12.2012
PT10.12.2012
Former [2013/23]AT08.08.2012
BE08.08.2012
CY08.08.2012
CZ08.08.2012
DK08.08.2012
EE08.08.2012
FI08.08.2012
IT08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
RO08.08.2012
SE08.08.2012
SI08.08.2012
SK08.08.2012
GR09.11.2012
ES19.11.2012
IS08.12.2012
PT10.12.2012
Former [2013/22]AT08.08.2012
BE08.08.2012
CY08.08.2012
CZ08.08.2012
DK08.08.2012
EE08.08.2012
FI08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
SE08.08.2012
SI08.08.2012
GR09.11.2012
ES19.11.2012
IS08.12.2012
PT10.12.2012
Former [2013/21]AT08.08.2012
BE08.08.2012
CY08.08.2012
DK08.08.2012
FI08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
SE08.08.2012
SI08.08.2012
GR09.11.2012
IS08.12.2012
PT10.12.2012
Former [2013/13]AT08.08.2012
BE08.08.2012
CY08.08.2012
FI08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
SE08.08.2012
SI08.08.2012
GR09.11.2012
IS08.12.2012
PT10.12.2012
Former [2013/12]AT08.08.2012
BE08.08.2012
CY08.08.2012
FI08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
SE08.08.2012
SI08.08.2012
GR09.11.2012
IS08.12.2012
Former [2013/11]AT08.08.2012
CY08.08.2012
FI08.08.2012
LT08.08.2012
LV08.08.2012
PL08.08.2012
SI08.08.2012
GR09.11.2012
IS08.12.2012
Former [2013/10]AT08.08.2012
CY08.08.2012
FI08.08.2012
LT08.08.2012
IS08.12.2012
Former [2013/09]AT08.08.2012
FI08.08.2012
LT08.08.2012
Former [2013/08]AT08.08.2012
LT08.08.2012
Former [2013/07]AT08.08.2012
Documents cited:Search[X]WO03099862  (APPLIED NANOSYSTEMS BV [NL]; MOLL GERT NIKOLAAS [NL]; LEENHOUTS CORNEL) [X] 1-3,7-11 * accession number P00750: disulfide bridge 110-119; page 59 - page 60 *;
 [A]  - QI RUI-FENG ET AL, "Structural features and molecular evolution of Bowman-Birk protease inhibitors and their potential application", ACTA BIOCHIMICA ET BIOPHYSICA SINICA, BLACKWELL PUBLISHING, INC., MALDEN, MA, US LNKD- DOI:10.1111/J.1745-7270.2005.00048.X, (20050501), vol. 37, no. 5, ISSN 1672-9145, pages 283 - 292, XP002524245 [A] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1745-7270.2005.00048.x
International search[A]US2003166003  (COCHRAN ANDREA G [US], et al)
 [A]  - MAGALHAES G.S. ET AL., "Natterins, a new class of proteins with kininogenase activity characterized from Thalassophryne nattereri fish venom", BIOCHIMIE, (200508), vol. 87, no. 8, pages 687 - 699, XP004996881

DOI:   http://dx.doi.org/10.1016/j.biochi.2005.03.016
by applicant   - RUI FENG ET AL., "Structural Features and Molecular Evolution of Bowman-Birk protease inhibitors and their potential application", ACTA BIOCHIMICA ET BIOPHYSICA SINICA, (2005), vol. 37, no. 5, doi:doi:10.1111/j.1745-7270.2005.00048.x, pages 283 - 292, XP002524245

DOI:   http://dx.doi.org/10.1111/j.1745-7270.2005.00048.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.